TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Wall Street Lead
Play
MARKETS

S&P 500 Closes at Record; Stocks Extend Win Streak to Four

  • By Joseph Woelfel
  • 20 hours ago
Ready to Trade Bristol-Myers Squibb, Bank of America, CSX? Here's What to Know
INVESTING

Bristol-Myers Flat After Report - Here's the Must-Hold Support Level

  • By Bret Kenwell
  • 23 hours ago
47 Quarterly Dividend Declared By Merck
INVESTING

When to Buy Merck as Shares Fall After Earnings

  • By Bret Kenwell
  • Feb 4, 2021 11:29 AM EST
Merck Second-Quarter Results Beat Forecasts
INVESTING

Merck, Bristol Myers Squibb, PayPal, Apple - Thursday's Premarket Movers

  • By Vidhi Choudhary
  • Feb 4, 2021 8:33 AM EST
Merck Is Benefiting From Keytruda, but Jim Cramer Prefers Eli Lilly
INVESTING

Merck Misses Q4 Earnings Forecast; CEO Ken Frazier to Retire

  • By Martin Baccardax
  • Feb 4, 2021 9:37 AM EST
PRESS RELEASES

Kenneth C. Frazier To Retire As Merck CEO; Board Elects Robert M. Davis As Successor; Frazier To Continue As Executive Chairman

  • By Business Wire
  • Feb 4, 2021 6:40 AM EST
Trader New York Stock Exchange Lead
MARKETS

Stimulus Checks, PayPal, Dogecoin, Merck, Ford - 5 Things You Must Know Thursday

  • By Joseph Woelfel
  • Feb 4, 2021 8:31 AM EST
Wall Street Lead
MARKETS

Stocks End Higher as Retail Trading Frenzy Ebbs, Nasdaq Jumps 2.6%

  • By Joseph Woelfel
  • Feb 1, 2021 4:21 PM EST
PRESS RELEASES

Dr. Stephen Mayo Elected To Merck Board Of Directors

  • By Business Wire
  • Feb 1, 2021 6:45 AM EST
Lufax is set to make the biggest splash on the NYSE by a Chinese company since e-commerce giant Alibaba's IPO in 2014. Photo: Reuters
INVESTING

Dow Futures Rebound, Silver Surges To Seven-Year High As Reddit Retail Army Targets Metals

  • By Martin Baccardax
  • Feb 1, 2021 9:10 AM EST
NYSE Lead
MARKETS

Silver, GameStop, Robinhood, Amazon, Exxon and Chevron - 5 Things You Must Know Monday

  • By Joseph Woelfel
  • Feb 1, 2021 8:06 AM EST
PRESS RELEASES

Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) In Combination With Ipilimumab Versus KEYTRUDA Monotherapy In Certain Patients With Metastatic Non-Small Cell Lung Cancer

  • By Business Wire
  • Jan 29, 2021 7:23 PM EST
PRESS RELEASES

Merck Announces Second Cohort Of Safer Childbirth Cities Organizations Committed To Improving Maternal Health Equity And Reducing Preventable Maternal Deaths In The US

  • By Business Wire
  • Jan 27, 2021 8:00 AM EST
PRESS RELEASES

Merck Announces Second-Quarter 2021 Dividend

  • By Business Wire
  • Jan 26, 2021 1:15 PM EST
PRESS RELEASES

Merck Presents Interim Findings From Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir For The Prevention Of HIV-1 Infection At HIVR4P 2021

  • By Business Wire
  • Jan 26, 2021 9:06 AM EST
Video: Jim Cramer Has a Way to Play California Marijuana Legalization
INVESTING

Buy-the-Dip Candidates in the Stock Market: Aurora Cannabis Falls

  • By Danny Peterson
  • Jan 25, 2021 9:46 AM EST
Gamestop Lead
INVESTING

GameStop, Tesla, Apple, AMC - Monday's Premarket Movers

  • By Vidhi Choudhary
  • Jan 25, 2021 8:12 AM EST
Merck Is Benefiting From Keytruda, but Jim Cramer Prefers Eli Lilly
INVESTING

Merck Dumps COVID Vaccine Program After Poor Immune Response in Early Trials

  • By Martin Baccardax
  • Jan 25, 2021 9:40 AM EST
PRESS RELEASES

Merck Discontinues Development Of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development Of Two Investigational Therapeutic Candidates

  • By Business Wire
  • Jan 25, 2021 6:45 AM EST
PRESS RELEASES

Merck Announces U.S. FDA Approval Of VERQUVO® (vericiguat)

  • By Business Wire
  • Jan 20, 2021 6:45 AM EST
Gilead-5f0876a85129505ee26e208e_Jul_10_2020_14_18_12
INVESTING

Gilead Up on Patent-Dispute Win and Morgan Stanley Upgrade

  • By Dan Weil
  • Jan 19, 2021 1:35 PM EST
PRESS RELEASES

U.S. FDA Accepts For Priority Review The Biologics License Application For V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine, For Use In Adults 18 Years Of Age And Older

  • By Business Wire
  • Jan 12, 2021 6:45 AM EST
PRESS RELEASES

Merck To Hold Fourth-Quarter And Full-Year 2020 Sales And Earnings Conference Call On February 4

  • By Business Wire
  • Jan 8, 2021 6:45 AM EST
Wall Street Lead
INVESTING

5 Worst Stocks in the Dow on Wednesday: Intel Slips

  • By Vidhi Choudhary
  • Dec 30, 2020 5:52 PM EST
Kangji Medical Investor Sees More Health Care Start-ups Opting For A Hong Kong Listing
INVESTING

Best Healthcare Stocks to Buy in 2021

  • By Stephen Guilfoyle
  • Jan 30, 2021 11:35 AM EST
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.